RÉSUMÉ DIGEST
ACT 412 (SB 118) 2022 Regular Session Talbot
New law requires a health coverage plan in this state to include coverage for genetic or
molecular testing for cancer including but not limited to tumor mutation testing, next
generation sequencing, hereditary germline mutation testing, pharmacogenomic testing,
whole exome and genome sequencing, and biomarker testing. New law retains prior law.
New law provides that coverage may be subject to annual deductibles, coinsurance, and
copayments established under a health coverage plan. New law retains prior law.
New law provides that coverage may be subject to applicable evidence-based medical
necessity criteria of a health coverage plan. New law deletes prior law.
New law requires coverage for biomarker testing for the purposes of diagnosis, treatment,
appropriate management, or ongoing monitoring of an individual's disease or condition when
the diagnostic test is supported in certain respects by any of the following: the U.S. Food and
Drug Administration (FDA), Centers for Medicare and Medicaid Services National
Coverage Determinations, Medicare Administrative Contractor Local Coverage
Determinations, National Comprehensive Cancer Network, or American Society of Clinical
Oncology.
New law defines "biomarker testing". New law expands the definition to include whole
exome and whole transcriptome sequencing. Otherwise retains the prior law definition.
New law defines "health coverage plan" but new law provides that "health coverage plan"
does not include any plan offered through the office of group benefits.
New law defines "consensus statements" and "nationally recognized clinical practice
guidelines".
Effective January 1, 2023.
(Amends R.S. 22:1028.3(B)(2), (C), and (D)(intro para) and (2); adds R.S. 22:1028.3(D)(3)
and (4))